npj Breast Cancer · 2024 · 19 citations · 46 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoveryMolecular OncologyBiomarker-guided Therapy SelectionCancer BiomarkersMolecular ScreeningMolecular Tumor ProfilingTargeted Cancer TherapyCancer Cell Proliferation InhibitionCdk InhibitorsCell Cycle InhibitionCell Proliferation Inhibition AssaysCyclin-dependent Kinase 4/6 InhibitorsG1 Phase ArrestProliferation AssaysProtein Kinase Inhibitors
CDK4/6 inhibitors are effective at treating advanced HR+ /HER2- breast cancer, however biomarkers that can predict response are urgently needed. We demonstrate here that previous large-scale screens designed to identify which tumour types or genotypes are most sensitive to CDK4/6 inhibitors have misrepresented the responsive cell lines because of a reliance on metabolic proliferation assays. CDK4/6-inhibited cells arrest in G1 but continue to grow in size, thereby producing more mitochondria. We show that this growth obscures the arrest using ATP-based proliferation assays but not if DNA-based assays are used instead. Furthermore, lymphoma lines, previously identified as the most sensitive, simply appear to respond the best using ATP-based assays because they fail to overgrow during the G1 arrest. Similarly, the CDK4/6 inhibitor abemaciclib appears to inhibit proliferation better than palbociclib because it also restricts cellular overgrowth through off-target effects. DepMap analysis of screening data using reliable assay types, demonstrates that palbociclib-sensitive cell types are also sensitive to Cyclin D1, CDK4 and CDK6 knockout/knockdown, whereas the palbociclib-resistant lines are sensitive to Cyclin E1, CDK2 and SKP2 knockout/knockdown. Potential biomarkers of palbociclib-sensitive cells are increased expression of CCND1 and RB1, and reduced expression of CCNE1 and CDKN2A. Probing DepMap with similar data from metabolic assays fails to reveal these associations. Together, this demonstrates why CDK4/6 inhibitors, and any other anti-cancer drugs that arrest the cell cycle but permit continued cell growth, must now be re-screened against a wide-range of cell types using an appropriate proliferation assay. This would help to better inform clinical trials and to identify much needed biomarkers of response.
46
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett, Elena J. Edelman, Sonja J. Heidorn et al. · Nature · 2012 · 2.6K citations · Full text
Medicine, Cancer Biology, Oncology +16
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio, Theo Knijnenburg, Daniël J. Vis et al. · Cell · 2016 · 2.3K citations · Full text
Medicine, Cancer Biology, Oncology +17
Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations
Medicine, Oncology, Pharmacology +17
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Andrea C. Carrano, Esther Eytan, Avram Hershko et al. · Nature Cell Biology · 1999 · 1.5K citations